James P Campbell1, Erin Burton2, Shelly Wymer3, Michael Shaw4, Byron P Vaughn4. 1. Department of Internal Medicine, University of Minnesota, MMC 36, 420 Harvard St. SE, Minneapolis, MN, 55455, USA. jpcampbell@uwalumni.com. 2. College of Pharmacy, University of Minnesota, Minneapolis, MN, USA. 3. Office of Measurement Services, University of Minnesota, Minneapolis, MN, USA. 4. Division of Gastroenterology, Department of Internal Medicine, University of Minnesota, Minneapolis, MN, USA.
Abstract
BACKGROUND: Therapeutic drug monitoring (TDM) is increasingly performed to optimize biologic therapy in inflammatory bowel disease (IBD). However, patients and physicians may be reluctant to perform TDM due to concerns related to potential out-of-pocket costs. AIMS: The aim of this study was to evaluate patient understanding and attitudes toward TDM in different clinical scenarios with and without potential out-of-pocket costs. METHODS: Adult IBD patients at a tertiary gastroenterology clinic were anonymously surveyed from March to September 2016 to assess their understanding of and willingness to undergo TDM in a variety of clinical scenarios, both with and without a potential out-of-pocket cost. Responses were analyzed for associations with changes in attitudes if out-of-pocket costs were involved. RESULTS: Of 118 completed surveys, 68.2% of patients were aware of or had previously undergone TDM. Patient willingness to undergo TDM was high both with and without potential out-of-pocket costs (70 and 98%, respectively); however, patients were significantly less willing with out-of-pocket cost (p < 0.01). Higher disease-related quality of life scores, as measured by the short inflammatory bowel disease questionnaire (SIBDQ), was significantly associated with an increased willingness to assume a potential out-of-pocket cost (p = 0.007). CONCLUSIONS: Overall, patients understand and are willing to undergo TDM in certain potentially beneficial clinical scenarios, however, are significantly less willing if paying out-of-pocket. A higher SIBDQ score was associated with an increase in willingness to undergo TDM when out-of-pocket cost was involved. Physicians should discuss TDM with their patients in order to make an informed and personalized treatment decision.
BACKGROUND: Therapeutic drug monitoring (TDM) is increasingly performed to optimize biologic therapy in inflammatory bowel disease (IBD). However, patients and physicians may be reluctant to perform TDM due to concerns related to potential out-of-pocket costs. AIMS: The aim of this study was to evaluate patient understanding and attitudes toward TDM in different clinical scenarios with and without potential out-of-pocket costs. METHODS: Adult IBDpatients at a tertiary gastroenterology clinic were anonymously surveyed from March to September 2016 to assess their understanding of and willingness to undergo TDM in a variety of clinical scenarios, both with and without a potential out-of-pocket cost. Responses were analyzed for associations with changes in attitudes if out-of-pocket costs were involved. RESULTS: Of 118 completed surveys, 68.2% of patients were aware of or had previously undergone TDM. Patient willingness to undergo TDM was high both with and without potential out-of-pocket costs (70 and 98%, respectively); however, patients were significantly less willing with out-of-pocket cost (p < 0.01). Higher disease-related quality of life scores, as measured by the short inflammatory bowel disease questionnaire (SIBDQ), was significantly associated with an increased willingness to assume a potential out-of-pocket cost (p = 0.007). CONCLUSIONS: Overall, patients understand and are willing to undergo TDM in certain potentially beneficial clinical scenarios, however, are significantly less willing if paying out-of-pocket. A higher SIBDQ score was associated with an increase in willingness to undergo TDM when out-of-pocket cost was involved. Physicians should discuss TDM with their patients in order to make an informed and personalized treatment decision.
Entities:
Keywords:
Health expenditures; Inflammatory bowel disease; Patient preferences; Therapeutic drug monitoring
Authors: Filip Baert; Maja Noman; Severine Vermeire; Gert Van Assche; Geert D' Haens; An Carbonez; Paul Rutgeerts Journal: N Engl J Med Date: 2003-02-13 Impact factor: 91.245
Authors: Casper Steenholdt; Jørn Brynskov; Ole Ø Thomsen; Lars K Munck; Jan Fallingborg; Lisbet A Christensen; Gitte Pedersen; Jens Kjeldsen; Bent A Jacobsen; Anne Sophie Oxholm; Jakob Kjellberg; Klaus Bendtzen; Mark A Ainsworth Journal: Dig Dis Sci Date: 2015-02-12 Impact factor: 3.199
Authors: Fernando S Velayos; James G Kahn; William J Sandborn; Brian G Feagan Journal: Clin Gastroenterol Hepatol Date: 2013-01-26 Impact factor: 11.382
Authors: Freddy Cornillie; Stephen B Hanauer; Robert H Diamond; Jianping Wang; Kezhen L Tang; Zhenhua Xu; Paul Rutgeerts; Séverine Vermeire Journal: Gut Date: 2014-01-28 Impact factor: 23.059
Authors: Diana M Negoescu; Eva A Enns; Brooke Swanhorst; Bonnie Baumgartner; James P Campbell; Mark T Osterman; Konstantinos Papamichael; Adam S Cheifetz; Byron P Vaughn Journal: Inflamm Bowel Dis Date: 2020-01-01 Impact factor: 5.325